Dietary Fasted

OTHER3 trials

Sponsors

AstraZeneca

Conditions

Advanced (Inoperable) Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerSolid Tumours

Phase 1

D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours

CompletedNCT01851265

AstraZenecaSolid Tumours

Start: 2013-07-04End: 2017-06-06Updated: 2017-08-28

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

CompletedNCT01921140

AstraZenecaSolid Tumours

Start: 2013-09-24End: 2022-03-15Updated: 2022-11-22

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

CompletedNCT02163733

AstraZenecaAdvanced (Inoperable) Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

Start: 2014-11-14End: 2023-01-24Updated: 2024-01-22

Related Papers

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers

The Journal of Clinical Pharmacology2017-11-2654 citations

Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.

2016-08-2312 citations

Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291

Molecular Cancer Therapeutics2015-12-0110 citations

Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation.

Journal of Clinical Oncology2014-05-204 citations